Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL2689 Target Snapshot

Macrophage-stimulating protein receptor · SINGLE PROTEIN · Homo sapiens

Back to Search Search this target Browse approvals Evidence Card
1,676Compounds
378Assays
13Approved Drugs
920.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Research home Demo workspace
Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Macrophage-stimulating protein receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs keep the current disease frame grounded. Protein identity stays anchored to UniProt Q04912. Start with cancer, then reuse UniProt Q04912 as the stable protein anchor across project notes and exports.

Review focus
Review-ready target frame

Start with cancer, then reuse UniProt Q04912 as the stable protein anchor across project notes and exports.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13 4 linked drugs
Open source guide
Disease program
cancer

Macrophage-stimulating protein receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block. 4 linked drugs remain visible in the same block.

Start review with cancer because it currently carries approved-linked support. Linked drugs include CRIZOTINIB, GLESATINIB, MK-8033, NARNATUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Disease source · ChEMBL drug mechanism + indication proxy
Approved-linked Open Targets-ready proxy 4 linked drugs
Open disease block
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Macrophage-stimulating protein receptor as ChEMBL target CHEMBL2689, mapped to UniProt Q04912. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Macrophage-stimulating protein receptor
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL2689
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q04912
Macrophage-stimulating protein receptor
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Macrophage-stimulating protein receptor is the right protein anchor across sources, using UniProt Q04912 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need to confirm why cancer is currently framed as approved-linked support. It currently carries 4 linked drugs in the same disease frame.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

Preferred NameMacrophage-stimulating protein receptor
Target TypeSINGLE PROTEIN
OrganismHomo sapiens
UniProtQ04912
ChEMBL ↗ UniProt ↗ NCBI Protein ↗

Next Actions

SearchRun a focused querySearch the database using this target name as the starting context. ApprovalsCheck approved moleculesSee which approved drugs connect back to this target and its surrounding signal space. FeedScan papers & updatesStay in the project thread while checking recent papers and platform updates.
UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelMacrophage-stimulating protein receptor
UniProt AccessionQ04912
Component TypeProtein
Sequence Length1400 aa

Macrophage-stimulating protein receptor

Source · UniProt accession via ChEMBL component mapping
UniProt Context ↗
Review Cue

How to read this target

Review this target as Macrophage-stimulating protein receptor, mapped to UniProt Q04912. Sequence length is 1400 aa.

Mapped IDQ04912
Review nameMacrophage-stimulating protein receptor
OrganismHomo sapiens
Disease Relevance

Disease Relevance & Evidence Level

Open Targets-ready disease context using the current target-indication evidence contract.

Approved-linked Open Targets-ready proxy

Macrophage-stimulating protein receptor shows approved-linked disease relevance led by cancer. 5 more disease programs remain visible in the same review block.

Approved-linked Approved
cancer
4 linked drugs · 4 direct · 4 efficacy
Linked drugCRIZOTINIB
Linked drugGLESATINIB
Linked drugMK-8033
Linked drugNARNATUMAB
Approved-linked Approved
non-small cell lung carcinoma
2 linked drugs · 2 direct · 2 efficacy
Linked drugCRIZOTINIB
Linked drugGLESATINIB
Approved-linked Approved
neoplasm
1 linked drug · 1 direct · 1 efficacy
Linked drugCRIZOTINIB
Late clinical Phase III
carcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCRIZOTINIB
Late clinical Phase III
lung adenocarcinoma
1 linked drug · 1 direct · 1 efficacy
Linked drugCRIZOTINIB
Late clinical Phase III
lung cancer
1 linked drug · 1 direct · 1 efficacy
Linked drugCRIZOTINIB
Source · ChEMBL drug mechanism + indication proxy
ChEMBL target record ↗
Review Cue

How to read disease relevance

Start review with cancer because it currently carries approved-linked support. Linked drugs include CRIZOTINIB, GLESATINIB, MK-8033, NARNATUMAB. This disease block keeps the Open Targets-ready contract explicit while current evidence comes from ChEMBL mechanism and indication mappings.

Lead diseasecancer
Strongest levelApproved-linked
Block modeOpen Targets-ready proxy
Clinical Profile

Clinical Phase Distribution

13
Approved
7
Phase III
22
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC50256.0
KI337.0
EC502.0
KD325.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL5430218 9.8 IC50 0.16 Preclinical
CHEMBL1980995 9.6 Ki 0.2512 Preclinical
CHEMBL5427445 9.59 IC50 0.26 Preclinical
CHEMBL5419134 9.55 IC50 0.28 Preclinical
CHEMBL5396164 9.41 IC50 0.39 Preclinical
CHEMBL5404435 9.39 IC50 0.41 Preclinical
CHEMBL5411457 9.32 IC50 0.48 Preclinical
CHEMBL5421161 9.32 IC50 0.48 Preclinical
CHEMBL5440908 9.31 IC50 0.49 Preclinical
CHEMBL5398932 9.21 IC50 0.62 Preclinical
Distribution

pChEMBL Value Distribution

22
5.0
63
5.5
67
6.0
47
6.5
43
7.0
38
7.5
27
8.0
26
8.5
16
9.0
4
9.5
pChEMBL
Approved Drugs

Approved Drugs

ENTRECTINIB
CHEMBL1983268
Approved 2019
Properties Compare Identifier
GILTERITINIB
CHEMBL3301622
Approved 2018
Properties Compare Identifier
CABOZANTINIB
CHEMBL2105717
Approved 2012
Properties Compare Identifier
CRIZOTINIB
CHEMBL601719
Approved 2011
Properties Compare Identifier
Assay Landscape

Assay Landscape

378
Total Assays
184
Tested Compounds
2
Assay Types
Binding — 376 assays, 184 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 308 94 7.2
assay format 35 3 6.7
cell-based format 27 69 7.6
subcellular format 6 18 6.2
Functional — 2 assays, 154 compounds
BAO Format Assays Compounds Avg pChEMBL
assay format 1 153 6.0
cell-based format 1 1 6.8

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine